<DOC>
	<DOCNO>NCT02461121</DOCNO>
	<brief_summary>Patients de novo AML enrol study . Patient HLA-identical donor assign receive NST therapy GVHD prophylaxis HLA-identical donor assign receive MST therapy without GVHD prophylaxis .</brief_summary>
	<brief_title>HLA-mismatched MST v HLA-matched NST AML Intermediate-risk</brief_title>
	<detailed_description>The optimal therapy intermediate-risk patient acute myeloid leukemia ( AML ) first complete remission ( CR1 ) uncertain . Recent study show microtransplantation ( MST ) improve survival AML-CR1 patient . However , comparison study MST nonmyeloablative stem cell transplantation ( NST ) lacking . 156 intermediate-risk AML-CR1 patient age 9 59 year enrol study . Patients de novo AML enrol study . Patient HLA-identical donor assign receive NST therapy GVHD prophylaxis HLA-identical donor assign receive MST therapy without GVHD prophylaxis .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Patients must elderly ( 959 age ) AML pathologically confirm per WHO guideline . Patients WITH intermediaterisk AMLCR1 Patients must ECOG Performance status 0,1 , 2 . If ECOG 2 . Patients must HLA mismatch donor able provide inform consent . All gender race eligible . ALT AST≤3 ×ULN , TBIL≤1.5 × ULN , Cr≤2 ×ULN CrCl≥40 mL/min By mean ultrasonic Heartbeat map multiple gated acquisition ( MUGA ) scan determination LVEF normal range . Donors must able safely undergo leukapheresis . receive operation 4 week randomization acute promyelocytic leukemia , Myeloid sarcoma , chronic myeloid leukemia accelerate phase blastic phase ; active CNS disease , pregnancy , major medical psychiatric illness could compromise tolerance protocol Require use warfarin equivalent vitamin K antagonist ( phenprocoumon ) anticoagulant . There clinical significance cardiovascular disease , uncontrolled symptomatic arrhythmia , congestive heart failure myocardial infarction within 6 month randomization , heart function grade 3 ( moderate ) 4 ( severe ) heart disease accordance functional classification method New York Heart Association ( NYHA ) . Known follow history : human immunodeficiency virus ( HIV ) active hepatitis C virus hepatitis B virus infection Any situation process PI damage patient safety . Patients / authorized family member refuse sign consent . attend clinical researcher 3 month . Donors exclusion criterion include : active infection malignancy , cardiovascular instability , severe anemia , severe coagulation disorder , pregnancy , inadequate venous access , inability provide consent , condition deem unsafe treatment staff .</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>microtransplantationHLA-mismatched microtransplantation</keyword>
	<keyword>nonmyeloablative stem cell transplantation</keyword>
	<keyword>graft-versus-host disease</keyword>
</DOC>